drugset / Trial / NCT06567314

Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma

NCT06567314

NaSingle-groupOpen-labelTreatment

Summary

To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.

Timeline

Start
2024-12-02
Primary completion
2028-09-01
Completion
2030-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivonescimab Monoclonal antibody Oral